Medtronic Announces Launch of Its Latest Generation SAVR in Western Europe at EACTS Annual MeetingAvalus Ultra。Avalus UltraSpecifically designed for implantation and lifelong patient management, it is Medtronic's most advanced surgical aortic tissue valve, building on a decade of clinical experience with Avalus.And inLast week,Avalus UltraCompleted in GermanyFirst CaseImplantation。
"We are thrilled to further expand the use of the Avalus Ultra valve by launching it in Western Europe at the prestigious EACTS annual meeting. The introduction of the Avalus Ultra valve builds on several successful innovations this year, including the acquisition and launch of the Penditure Left Atrial Appendage Closure Device and VitalFlow ECMO, making Medtronic's cardiac surgery portfolio the strongest in the industry today. This further underscores the company’s commitment to bold investments in innovations across a range of cardiovascular and respiratory therapies to advance treatment options for more complex conditions and address the growing needs of clinicians to comprehensively manage patients throughout their lifetime."---Karim Bandali President of Cardiac Surgery Business, Medtronic Cardiovascular PortfolioIn the field of structural heart disease, aortic valve stenosis has always been the most important focus for Medtronic in the field of structural heart disease.Business.To this end, Medtronic has invested a significant amount of funds in this field in order to compete with Edwards. As a result, Medtronic has demonstrated a very "aggressive" business strategy.In terms of TAVR, Medtronic continuously iterates the Evolut series and conducts extensive clinical research to validate its efficacy.Evolut Series Non-Inferior to SAVR (Even better than SAVR) and superior to other TAVR products (especially in female patients, Evolut has clinically proven to be better thanSapien Forces Edwards to Make Major Adjustments). These investments have enabled Medtronic to continuously expandZhangIn the TAVR market share, the gap with Edwards is also gradually narrowing, and it may even surpass Edwards in the near future.In the SAVR field, although Medtronic's investment has not been as substantial as in TAVR, it continues to optimize and upgrade its SAVR products.Avalus UltraMedtronic's Latest Upgraded SAVR Product.Avalus UltraLet SAVRThe surgery becomes simpler, while also providing convenience for potential valve-in-valve surgeries in the future.
Avalus UltraIt is a bioprosthetic valve built on the previous generation of Medtronic's bioprosthetic valve.Aortic Bioprosthesis Optimized and Improved on the Basis of Avalus.AValus received FDA approval in 2017 and has clinical data spanning up to 10 years, confirming its long-term durability.InADuring the clinical use of Valus, Medtronic discovered some shortcomings and subsequently made improvements.AValus only needs to be upgraded---Avalus Ultra。
Avalus Ultra Compared toAValus, the upgrade is mainly reflected in three aspects:- IncreaseRadiopaque coils provide clear visibility for future valve-in-valve procedures.
These improvements in Avalus Ultra make valve implantation simple and easy, while providing visibility under DSA (X-ray) for potential future needs of valve-in-valve implantation.
In addition to these three optimizations,Avalus UltraAll have inherited the advantages of Avalus.
Avalus UltraRetain the valve processing technology with Avalus characteristics (AOA tissue）AOA Tissue-Processed Valves Show Calcification Resistance Close to EdwardsResilia-treated Technology.Avalus UltraWhile maintaining Avalus' industry-leading effective orifice area (EOA)`, enabling a greater blood flow.`
Besides,Avalus UltraAlso inherits Avalus' perfect suitability for valve-in-valve procedures, with specially designed leaflets effectively reducing the risk of coronary artery obstruction during valve-in-valve surgery.
Medtronic is one of the largest medical technology, services, and solutions companies in the world, alleviating pain, restoring health, and extending life for millions of people globally. With over 90,000 employees worldwide, Medtronic serves doctors, hospitals, and patients in more than 150 countries. The company is committed to collaborating with stakeholders around the world to advance healthcare.
